140
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Hyper-Reflective Outer Nuclear Layer (HONL) in Vogt–Koyanagi–Harada Disease and Sympathetic Ophthalmia

, MD, PhDORCID Icon, , MD, , MDORCID Icon, , MD, , MD, , MDORCID Icon & , MD, PhDORCID Icon show all
Pages 419-423 | Received 30 Jun 2022, Accepted 05 Oct 2022, Published online: 04 Nov 2022

References

  • Chu X, Chan C. Sympathetic ophthalmia: to the twenty-first century and beyond. J Ophthalmic Inflamm Infect. 2013;3(1):49. doi:10.1186/1869-5760-3-49.
  • Mahajan S, Invernizzi A, Agrawal R, Biswas J, Rao NA, Gupta V. Multimodal imaging in sympathetic ophthalmia. Ocul Immunol Inflamm. 2017 Apr;25(2):152–159. doi:10.1080/09273948.2016.1255339.
  • Yang P, Liu S, Zhong Z, et al. Comparison of clinical features and visual outcome between sympathetic ophthalmia and Vogt-Koyanagi-Harada disease in Chinese patients. Ophthalmology. 2019;126(9):1297–1305. doi:10.1016/j.ophtha.2019.03.049.
  • Yang P, Zhong Y, Du L, et al. Evaluation of diagnostic criteria for Vogt-Koyanagi-Harada disease. JAMA Ophthalmol. 2018 Sep 1;136(9):1025–1031. doi:10.1001/jamaophthalmol.2018.2664.
  • Agarwal A, Kb F, Kumar A, et al., OCTA Study Group. Bacillary layer detachment in acute Vogt-Koyanagi-Harada disease: a novel swept-source optical coherence tomography analysis. Retina. 2021 Apr 1;41(4):774–783. doi:10.1097/IAE.0000000000002914.
  • Parikh JG, Saraswathy S, Rao NA. Photoreceptor oxidative damage in sympathetic ophthalmia. Am J Ophthalmol. 2008 Dec;146(6):866–75.e2. doi:10.1016/j.ajo.2008.03.026.
  • Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. Oct 1994;35(11):3884–3889.
  • Kim MH, Seong MC, Kwak NH, et al. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol. 2000 Feb;129(2):173–177. doi:10.1016/S0002-9394(99)00434-1.
  • Ng JY, Luk FO, Lai TY, et al. Influence of molecular genetics in Vogt-Koyanagi-Harada disease. J Ophthal Inflamm Infect. 2014. 4(20). doi:10.1186/s12348-014-0020-1.
  • Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br J Ophthalmol. 2001;85(3):281–286. doi:10.1136/bjo.85.3.281.
  • Islam SM, Numaga J, Fujino Y, Matsuki K, Maeda H, Masuda K. Relation between the clinical course of Vogt-Koyanagi-Harada’s disease and human leukocyte antigen (HLA)-DR4 subtypes. Nippon Ganka Gakkai Zasshi. Aug 1994;98(8):797–800.
  • Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013 Sep;91(6):e486–93. doi:10.1111/aos.12127.
  • O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017 Jan-Feb;62(1):1–25. doi:10.1016/j.survophthal.2016.05.002.
  • Parchand S, Agrawal D, Ayyadurai N, et al. Sympathetic ophthalmia: a comprehensive update. Indian J Ophthalmol. 2022 Jun;70(6):1931–1944. doi:10.4103/ijo.IJO_2363_21.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.